Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cartier Silver Outlines an 800m by 500m Epithermal Silver Polymetallic Target on Gonalbert Property, Potosi Department, Southern Bolivia (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare Biotechnology
Appili Therapeutics Inc. is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-1701, ATI-1801 and ATI-1501.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSX:APLI)

Fundamentals Snapshot (TSX:APLI)

Current News (TSX:APLI)

Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole

Business Wire May 24, 2023

Appili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy

Business Wire May 8, 2023

Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 18, 2023

Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

Business Wire April 3, 2023

Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings

Business Wire March 20, 2023

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

Business Wire February 14, 2023

Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA

Business Wire February 8, 2023

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

Business Wire January 17, 2023

Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Business Wire January 13, 2023
View More News ››

Opinion & Analysis (TSX:APLI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:APLI)

Big bids coming in now.

What's up?
opsd1 - November 21, 2022

APLI Secures US$14 million from US DoD for Biodefense

Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership...
opsd1 - November 15, 2022

News Update w Radius Research and $APLI CEO Armand Balboni

News Update: Appili Therapeutics (APLI) w CEO Dr. Armand Balboni  - Develop Leishmaniasis Treatment ATI-1801 - https://www...
bmreed - April 14, 2022

yes, lots of potential and appears to be a well run

company but: * $3.6M they raised will be used almost in full to pay off the previous loan * the interest on the new loan will be at least...
ecanadian2 - April 12, 2022

Webinar Recap w Radius Research & $APLI CEO Armand Balboni

Webinar Recap: Appili Therapeutics (APLI) w CEO Dr. Armand Balboni - Drug Development Focused on Infectious Diseases - Pitch, Deep...
bmreed - April 11, 2022

Webinar w $APLI CEO Armand Balboni Fri Apr 8 @ 12:30PM ET

Webinar - Appili Therapeutics (APLI) w/ CEO Dr. Armand Balboni Fri, Apr 8 at 12:30pm ET / 9:30am PT Q&A with Radius Research...
bmreed - April 4, 2022
View more Bullboard ››

Nicola Mining Inc

Nicola Mining Inc

Nicola Mining Inc is engaged in the identification, acquisition, and exploration of mineral property interests. Its projects ...
View More »